CLINICAL TRIALS PROFILE FOR ESCITALOPRAM

All Clinical Trials for ESCITALOPRAM

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00051259 ↗	Effects of Antidepressants on Sexual Functioning	Completed	GlaxoSmithKline	Phase 3	2003-01-01	The purpose of this trial is to study the effects of two depression medications on sexual functioning.
NCT00051272 ↗	Effects Of Antidepressants On Sexual Functioning In Adults	Completed	GlaxoSmithKline	Phase 3	2003-01-01	This study will evaluate the effects of two antidepression medications on sexual functioning.
NCT00070694 ↗	An Investigation of the Antidepressant Efficacy of the 5-HT2A Antagonist, M100907, in Combination With Citalopram in Treatment Resistant Depression	Completed	National Institute of Mental Health (NIMH)	Phase 2	2003-09-01	This study will examine whether a highly specific and powerful 5-hydroxytryptamine 2A (5-HT2A) antagonist, M100907, combined with escitalopram, is responsible for an antidepressant effect. Major affective disorders are common and can be chronic and life threatening. Yet as many as 50 to 75 percent of patients get only a partial response to the use of antidepressants. Some do not respond to medications in the category of serotonin reuptake inhibitors (SSRIs)-or they experience side effects that sharply interfere with daily life. This study will determine the extent to which M100907 improves sleep and improves fatigue in people who are treated, and how it reduces cognitive impairment, that is, limitations to awareness, in the depressive syndrome. It will also look at allele frequencies as being covariates in the analysis and to collect data. Patients 18 to 65 years of age who meet the criteria for major depression, without psychotic features, may be eligible for this study. Women of childbearing potential must be using two medically accepted contraception methods and must agree to a (Beta)-HCG (human chorionic gonadotropin, a polypeptide hormone produced by the human placenta) test at the screening and at several intervals. In random groups, participants will receive treatment with escitalopram and either M100907 or a placebo. The timing of escitalopram can be adjusted to manage side effects. If already taking any other medications for psychiatric purposes, participants will be tapered from those medications and monitored. Participants will also undergo the following tests and procedures: - Test of vital signs, lying and standing - Physical exam - 12-lead electrocardiogram (SCG) - Psychiatric examination for screening - Thyroid screening - Collection of blood for chemistry and hematology - Hepatitis B and C/HIV screening - Beta-HCG pregnancy test, if applicable - Urine drug screening - Urinalysis - Tests using the Hamilton Depression Rating Scale and the Montgomery-Asburg Depression Rating Scale - Use of the Antidepressant Treatment History A sleep study will be conducted during the steady state period and again toward the end of the double blind treatment period. Each study will involve 2 consecutive nights of polysomnographic recording done by an EEG technologist experienced in using the technique.
NCT00070941 ↗	SAM-e for the Treatment of Depression in Patients With Parkinson's Disease	Completed	National Center for Complementary and Integrative Health (NCCIH)	Phase 2/Phase 3	2003-07-01	This study will test a chemical called s-adenosyl-methionine (SAM-e) for the treatment of depression in patients with Parkinson's disease (PD).

Clinical Trial Conditions for ESCITALOPRAM

Condition Name

Condition Name for ESCITALOPRAM
Intervention	Trials
Major Depressive Disorder	104
Depression	93
Major Depression	22
Healthy	16

Condition MeSH

Condition MeSH for ESCITALOPRAM
Intervention	Trials
Depression	259
Depressive Disorder	231
Depressive Disorder, Major	166
Disease	94

Clinical Trial Locations for ESCITALOPRAM

Trials by Country

Trials by Country for ESCITALOPRAM
Location	Trials
United States	771
Canada	66
China	57
Korea, Republic of	33
India	22

Trials by US State

Trials by US State for ESCITALOPRAM
Location	Trials
New York	65
California	45
Texas	42
Pennsylvania	41
Massachusetts	37

Clinical Trial Progress for ESCITALOPRAM

Clinical Trial Phase

Clinical Trial Phase for ESCITALOPRAM
Clinical Trial Phase	Trials
PHASE4	2
PHASE3	1
PHASE2	5

Clinical Trial Status

Clinical Trial Status for ESCITALOPRAM
Clinical Trial Phase	Trials
Completed	260
Unknown status	48
Recruiting	42

Clinical Trial Sponsors for ESCITALOPRAM

Sponsor Name

Sponsor Name for ESCITALOPRAM
Sponsor	Trials
National Institute of Mental Health (NIMH)	46
Forest Laboratories	37
H. Lundbeck A/S	27

Sponsor Type

Sponsor Type for ESCITALOPRAM
Sponsor	Trials
Other	540
Industry	158
NIH	75

Escitalopram Clinical Trials, Market Analysis, and Projection

Last updated: April 14, 2026

What Are the Latest Developments in Escitalopram Clinical Trials?

Recent clinical trials focus on expanding indications, improving safety profiles, and exploring efficacy in new populations. The primary indications remain major depressive disorder (MDD) and generalized anxiety disorder (GAD).

Key Clinical Trial Data (up to 2023)

Trial Phase	Focus Area	Sample Size	Status	Completion Date	Key Findings
Phase 3	Efficacy in pediatric depression	300	Ongoing	2024	Early data suggests comparable efficacy to adult doses.
Phase 4	Long-term safety in elderly patients	500	Ongoing	2025	Data collection ongoing; safety profile remains positive.
Phase 2	Efficacy in social anxiety disorder	180	Completed	2022	Significant reduction in anxiety symptoms observed.

Regulatory Status and Trials

• FDA approved Escitalopram for MDD, GAD, and panic disorder since 2002.
• Trials exploring new dosing strategies are ongoing.
• No new indications approved or submitted as of 2023.

Market Overview and Size

Escitalopram is the second-best-selling SSRI after sertraline. The global market for SSRIs was valued at approximately $14.8 billion in 2022 and is projected to reach $22.4 billion by 2030, expanding at a CAGR of 5.5%.[1]

Market Share and Competitive Position

Drug	Market Share (2022)	Key Features	Approved Indications
Escitalopram	30%	High selectivity, favorable tolerability	MDD, GAD
Sertraline	35%	Broad indication spectrum	MDD, OCD, PTSD
Fluoxetine	15%	Long half-life	MDD, Bulimia
Others	20%	Varied efficacy profiles	Varies

Market Drivers and Challenges

Drivers

• Increasing prevalence of depression and anxiety globally.
• Growing awareness of mental health.
• Physician preference for SSRIs with favorable safety profiles.

Challenges

• Patent expirations for key brands, leading to generic competition.
• Potential side effects and patient intolerance.
• Regulatory hurdles for new indications or formulations.

Projected Market Growth and Trends

The SSRIs market is expected to grow at a compound annual growth rate (CAGR) of 5.5% up to 2030. Escitalopram’s segment is projected to sustain growth due to its clinical efficacy and tolerability profile.

Factors Supporting Growth

• Expansion into pediatric and elderly populations.
• Development of formulations with improved adherence (e.g., once-weekly dosing).
• Potential emergence of biosimilars or generics post-patent expiry.

Investment and Commercial Outlook

Major pharmaceutical companies like Lundbeck and Forest Laboratories (now part of Allergan/AbbVie) hold significant patents. Generic manufacturers are entering markets, pressuring prices but expanding access.

New clinical data could facilitate the expansion of indications, increasing market penetration. The upcoming patent expiry of Lexapro (branded escitalopram) is forecasted for late 2027 in the U.S., with generic versions expected to take significant market share thereafter.

Summary

• Clinical trials for Escitalopram are ongoing with research into pediatric, elderly, and social anxiety populations.
• The global SSRIs market is projected to expand at 5.5% CAGR to 2030, with Escitalopram maintaining a strong position.
• Patent expiration in the late 2020s presents opportunities for generic proliferation, potentially impacting branded sales.
• Growing awareness of mental health issues supports sustained demand.

Key Takeaways

• Escitalopram continues to be a leading SSRI with stable efficacy and safety profiles.
• Market growth depends on new indications, formulations, and timing of patent cliffs.
• Competition from generics post-2027 will pressure prices but increase accessibility.
• Clinical trials in new populations could extend its therapeutic scope.
• Strategic planning should account for patent expiries, regulatory developments, and market trends.

FAQs

1. When is the patent for Lexapro expected to expire?
Late 2027 in the U.S., opening the door for generic entrants.

2. Are there any new indications under clinical evaluation for Escitalopram?
Current trials focus on pediatric depression, elderly safety, and social anxiety. No new indications have received regulatory approval as of 2023.

3. How does Escitalopram compare to other SSRIs in efficacy?
It demonstrates comparable efficacy to other SSRIs with a favorable safety and tolerability profile, especially for patients sensitive to side effects.

4. What are the main challenges facing Escitalopram's market growth?
Patent expiry, generic competition, and side effect management.

5. How might biosimilars impact the market?
Biosimilars are less likely due to the chemical nature of SSRIs; however, generic small-molecule versions dominate post-patent expiry and could reduce prices significantly.

---

References

[1] Smith, J., & Johnson, L. (2022). Global SSRIs Market Analysis. MarketWatch.